Cor Vasa 2025, 67(6):687-696

(Application of KDIGO guidelines for CKD diagnosis in clinical practice: cross-sectional study of eGFR and ACR testing in the Czech Republic)

Ivo Hlaváča, Miloš Táborskýb, Matěj Opatrnýc
1 Ústav epidemiologie a ochrany veřejného zdraví, Lékařská fakulta, Ostravská univerzita, Ostrava, Česká republika
2 Kardiologická klinika, Masarykova nemocnice, o.z., Krajská zdravotní, a.s., Ústí nad Labem, Česká republika
3 Institut ekonomických studií, Univerzita Karlova, Praha, Česká republika

Background: Chronic kidney disease (CKD) affects 9-13% of the global population. KDIGO guidelines recommend simultaneous albumin-to-creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR) testing for proper CKD staging. Data on compliance with these standards in Czech practice are lacking.

Methods: Cross-sectional retrospective analysis of 62,567 patients examined between January 2022 and April 2025 in Unilabs laboratories. We assessed availability of eGFR and ACR testing across specialties and compliance with KDIGO recommendations.

Results: Median age 67.0 years (IQR 54.3-75.4), 54% male. ACR was tested in 97.2% of patients, eGFR in only 3.3%. Complete eGFR + ACR testing for CKD staging was performed in only 0.5% of patients (n = 289). Nephrology showed the highest compliance (91% of all complete tests), general practitioners only 2.1%. CKD prevalence (eGFR <60 ml="" min="" 1="" 73="" m="" sup="">2 or ACR ≥3 mg/mmol) was 25.6%; after excluding nephrology examinations, it decreased to 21.5%. We demonstrated eGFR decline of 1.397 ml/min/1.73 m2/year of age (95% CI: -1.514 to -1.279; p <0.0001).

Conclusion: Compliance with KDIGO guidelines is critically low - only 0.5% of patients have complete testing. The main deficit is minimal eGFR utilization (3.3%), which laboratories do not routinely report. Implementation of automatic eGFR calculation, standardization of laboratory requests, and physician education are essential for improving early CKD diagnosis.

Keywords: Chronic kidney disease, eGFR, KDIGO, Screening, uACR

Received: October 4, 2025; Revised: October 12, 2025; Accepted: November 6, 2025; Prepublished online: June 2, 2012; Published: December 15, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hlaváč I, Táborský M, Opatrný M. (Application of KDIGO guidelines for CKD diagnosis in clinical practice: cross-sectional study of eGFR and ACR testing in the Czech Republic). Cor Vasa. 2025;67(6):687-696.
Download citation

Attachments

Download file000_Priloha_ONLINE_Taborsky.pdf

File size: 605.87 kB

References

  1. Sundström J, Bodegard J, Bollmann A, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2.4 million patients from 11 countries: The CaReMe CKD study. The Lancet Regional Health - Europe, Volume 2022;20:100438. Go to original source... Go to PubMed...
  2. Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet 2020;395:709-733. Go to original source... Go to PubMed...
  3. Parliamentary question | A systematic EU approach to chronic kidney disease | O-000006/2022 | European Parliament. [Online]. Dostupný z: Parliamentary question | A systematic EU approach to chronic kidney disease | O-000006/2022 | European Parliament. [citováno 2024-11-29].
  4. Coyle M, Flaherty G, Jennings CA. A critical review of chronic kidney disease as a risk factor for coronary artery disease. Int J Cardiol Heart Vasc 2021;35:100822. Go to original source... Go to PubMed...
  5. Kurella M, Lo JC, Chertow GM, et al. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults, J Am Soc Nephrol 2005;16:2134-2140. Go to original source... Go to PubMed...
  6. Go AS, Chertow GM, Fan D, et al. Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization. N Engl J Med 2004;351:1296-1305. Go to original source... Go to PubMed...
  7. Chen J, Muntner P, Hamm LL, et al. The Metabolic Syndrome and Chronic Kidney Disease in U.S. Adults. Ann Intern Med 2004:140:167-174. Go to original source... Go to PubMed...
  8. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2024;105(4S):S117-S314. Go to original source... Go to PubMed...
  9. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011) 2022;12:7-11. Go to original source... Go to PubMed...
  10. eGFR Calculator. Online. Dostupný z: https://www.kidney.org/professionals/gfr_calculator. [citováno 2025-12-03].
  11. Delgado C, Baweja M, Crews DC, et al. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. Am J Kidney Dis 2022;79:268-288.e1. Go to original source... Go to PubMed...
  12. Mei F, Gao Q, Chen F, et al. Frailty as a Predictor of Negative Health Outcomes in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. J Am Med Dir Assoc 2021;22:535-543.e7. Go to original source... Go to PubMed...
  13. 70/2012 Sb., Vyhláška o preventivních prohlídkách.
  14. Státní zdravotní ústav. Studie EHES - SZÚ. [Online]. Praha: Státní zdravotní ústav, Dostupné z: https://szu.gov.cz/temata-zdravi-a-bezpecnosti/studie-zdravotniho-stavu-obyvatelstva/dospeli/ehes/. [citováno 2025-09-24].
  15. Národní kardiovaskulární plán ČR na období 2025-2035. [Online]. Dostupné z: https://mzd.gov.cz/narodni-kardiovaskularni-plan-cr-na-obdobi-2025-2035/ [citováno 2025-09-24].
  16. 39/2012 Sb., Vyhláška o dispenzární péči.
  17. Viklický O, Rychlík I, Šonka P, et al. Doporučený postup ČNS pro diagnostiku a léčbu CKD u praktických lékařů | Česká nefrologická společnost, 2024. [Online]. Dostupné z: https://www.nefrol.cz/force-download/1786. [citováno 2025-09-24].
  18. Kurevija T, Šojat D, Bilić-Ćurčić I, et al. Barriers in prescribing antidiabetic medications with cardiovascular benefits: practice, experience, and attitudes of GPs in Croatia. BMC Prim Care 2025;26:143. Go to original source... Go to PubMed...
  19. Czupryniak L, Mosenzon O, Rychlík I, et al., Barriers to early diagnosis of chronic kidney disease and use of sodium-glucose cotransporter-2 inhibitors for renal protection: A comprehensive review and call to action. Diabetes Obes Metab. 2024;26:4165-4177. Go to original source... Go to PubMed...
  20. Pesce F, Pasculli D, Pasculli G, et al. The Disease Awareness Innovation Network for chronic kidney disease identification in general practice. J Nephrol 2022;35:2057-2065. Go to original source... Go to PubMed...
  21. Ryšavá R, Viklický O, Tesař V, et al. Doporučený postup pro praktické lékaře, ČNS 2023, Česká nefrologická společnost. [Online]. Dostupné z: https://www.nefrol.cz/force-download/1726. [citováno 2025-09-24].

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.